Financial Performance - The company reported a revenue of $XX million for the fiscal year, representing a YY% increase compared to the previous year[2] - The company achieved a revenue of RMB 164.2 million for the year ended December 31, 2024, representing an 8.5% increase compared to 2023[15] - Net profit for the year reached RMB 45.0 million, reflecting a growth of RMB 15.0 million from the previous year[17] - Gross profit reached RMB 119.3 million, reflecting a 35.2% increase from RMB 88.3 million in the previous year, with a gross margin of 72.7%, up 14.3 percentage points[51] - Revenue from consumer-grade genetic testing services and related products was RMB 159.6 million, a significant increase of 47.3% from RMB 108.4 million in 2023[49] - Revenue from cancer screening services dropped to RMB 4.6 million, a decline of 89.2% from RMB 42.9 million in 2023 due to strategic adjustments[69] - The cash flow from operating activities for the reporting period was RMB 57.2 million, primarily due to the profit generated during the reporting year[87] - The cash and cash equivalents decreased by 5.4% from RMB 518.3 million as of December 31, 2023, to RMB 490.3 million as of December 31, 2024[88] User Growth and Market Expansion - User data showed an increase in active users to ZZ million, up by AA% year-over-year[2] - The company is expanding its market presence, targeting E new regions, which is expected to enhance overall market share by F%[156] - The company is focused on further developing the consumer-grade genetic testing market in China, with expectations of market penetration increasing from 0.8% in 2020 to 11.6% by 2030[54] - The company completed an acquisition of a strategic partner for $FF million, expected to enhance operational capabilities[2] - Market expansion efforts include entering the European market, targeting a market share of EE% within the next two years[2] Research and Development - The company is investing $DD million in R&D for new technologies aimed at enhancing product offerings[2] - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions[56] - The company has developed 114 commercialized testing solutions in consumer-grade genetic testing and cancer screening, with 94 of these being self-developed services[21] - The company is developing eight in vitro diagnostic (IVD) pipeline products, including three consumer-grade genetic testing products expected to receive medical device registration certificates by 2025[22] - Research and development investment amounted to RMB 19.2 million, a year-on-year decrease of 14.3%[61] Corporate Governance and Management - The company has a strong leadership team with diverse backgrounds in healthcare, finance, and management, enhancing its strategic planning and operational efficiency[142] - The board consists of seven members, including three executive directors, one non-executive director, and three independent non-executive directors[164] - The company has established a mechanism for assessing board independence, which is reviewed annually, ensuring strong independent judgment within the board[176] - The company is committed to maintaining strong investor relations and financial strategy planning under the leadership of its CFO[131] - The company has received annual written confirmations of independence from all independent non-executive directors, affirming their status as independent individuals[175] Sustainability and Social Responsibility - The management emphasized a commitment to sustainability, aiming for a reduction in carbon emissions by II% over the next five years[2] - The company aims to integrate ESG principles into its operations, focusing on social responsibility and improving service accessibility[18] - The company aims to deliver sustainable returns to shareholders while ensuring customer satisfaction through high-quality products and services[160] Strategic Planning and Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of BB%[2] - New product launches are expected to contribute an additional $CC million in revenue in the upcoming quarter[2] - The company plans to enhance its marketing budget by HH% to boost brand awareness and customer engagement[2] - The company is exploring selective geographic expansion and acquisition opportunities to complement internal growth and enhance its existing product portfolio[59] Audit and Compliance - The company is undergoing an independent forensic investigation regarding audit issues as part of the resumption guidance from the stock exchange[107] - An independent internal control review is being conducted to ensure compliance with listing rules and to assess the adequacy of internal controls[108] - The company has been suspended from trading on the Hong Kong Stock Exchange since April 1, 2025, pending compliance with resumption guidance[102] Diversity and Inclusion - The board consists of 7 directors, with 4 male and 3 female members, achieving a gender diversity target of at least 2 female directors[198] - The board's gender ratio is 42.9% female and 57.1% male, while the overall employee gender ratio is 58.5% female and 41.5% male[199] - The senior management team has a gender ratio of 30% female and 70% male, indicating a focus on gender diversity at higher levels[199] - The company has adopted measurable goals to enhance board diversity, including a commitment to gender diversity in senior management recruitment[200]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 美因基因有限公司 | | | | | | 呈交日期: | 2026年2月2日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 06667 | 說明 | | | | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.2.0 FF301 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 500,000,000 USD 0.0001 USD 50,000 增加 / 減少 (-) USD III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） 不適用 第 3 頁 共 10 頁 v 1. ...

Core Viewpoint - The company, Mei Yin Gene (06667.HK), reported a revenue of RMB 164 million for the fiscal year ending December 31, 2024, representing an 8.5% year-on-year growth, and a net profit of RMB 45 million, with a 50.0% increase in net profit compared to the previous year, driven by product innovation and market expansion strategies [1]. Group 1 - The company achieved a revenue of RMB 164 million, reflecting an 8.5% increase year-on-year [1] - The net profit reached RMB 45 million, showing a significant growth of 50.0% year-on-year [1] - The growth is attributed to the company's focus on product design innovation, enriching the product matrix, and optimizing product structure [1] Group 2 - The company has established partnerships with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network [1] - The sales and marketing network enables the company to provide genetic testing services to a large portion of the Chinese population [1] - Collaborations with various e-commerce and online healthcare platforms have been initiated to expand and improve the sales and marketing network [1]

Core Viewpoint - Meigen Gene (06667) reported a revenue of approximately 164 million yuan for 2024, representing a year-on-year growth of 8.5% and a net profit of 45 million yuan, which is a 50.0% increase compared to the previous year [1] Group 1 - The company achieved earnings per share of 0.22 yuan [1] - The growth in revenue and net profit is attributed to the company's commitment to product design innovation and continuous enhancement of its product matrix and structure [1] - The company has adopted an active market expansion strategy, exploring more sales scenarios and channels to tap into potential market demand and sales opportunities [1] Group 2 - The establishment of a diversified sales system has further improved customer service experience, contributing to steady growth in revenue and net profit [1]

Core Viewpoint - Meigen Gene (06667) reported a revenue of approximately 164 million yuan for 2024, representing a year-on-year growth of 8.5%, and a net profit of 45 million yuan, reflecting a 50% increase [1] Group 1 - The company's revenue growth is attributed to its commitment to product design innovation and continuous enrichment of its product matrix [1] - The company has optimized its product structure and adopted proactive market expansion strategies [1] - Meigen Gene is exploring more sales scenarios and channels to tap into potential market demand and sales opportunities [1] Group 2 - The company has established a diversified sales system to enhance customer service experience [1] - These efforts have contributed to the steady growth of both revenue and net profit [1]

於 本 公 告 中，「我 們」指 本 公 司 及（如 文 義 所 指）本 集 團。本 公 告 所 載 若 干 金 額 及 百 分比數字已作約整。如任何表格的總數與所列數額的總和有任何不符之處，皆為 約 整 所 致。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 本 公 司 刊 發 日 期 為2022年6月 10日的招股章程所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 截 至2024年12月31日止年度的 年度業績公告 美 因 基 因 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2024年12月31日 止 年 度（「報告期」）的 綜 合 業 績。 業務回顧及展望 業績回顧 概 覽 作為中國領先的基 ...

承董事會命 美因基因有限公司 執行董事兼主席 林琳 香港，2026年1月25日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號： 6667） 董事會會議召開日期 美因基因有限公司（「本公司」連同其附屬公司「本集團」）董事（「董事」）會（「董事會」） 茲通告謹定於2026年2月4日（星期三）舉行董事會會議，以考慮及通過本集團截至2025年 6月30日止的六個月中期業績公告及其發佈，派發中期股息（如有），以及處理其他事項。 * 僅供識別 於本公告日期，本公司執行董事為俞熔博士、林琳女士及姜晶女士；非執行董事為郭美 玲女士，及獨立非執行董事為張影博士、賈慶豐先生及謝丹博士。 ...

格隆汇1月20日丨美因基因(06667.HK)公告，谨定于2026年1月30日举行公司董事会会议，以考虑及通过 集团截至2024年12月31日止年度的全年业绩公告及其发布，及建议末期股息(如有)，以及处理其他事 项。 ...

美因基因有限公司（「本公司」，連同其附屬公司「本集團」）董事會（「董事會」）兹通告謹 定於2026年1月30日舉行本公司董事會會議，以考慮及通過本集團截至2024年12月31日 止年度的全年業績公告及其發佈，及建議末期股息（如有），以及處理其他事項。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號： 6667） 董事會召開日期 香港，2026年1月20日 於本公告日期，本公司執行董事為俞熔博士、林琳女士及姜晶女士；非執行董事為 郭美玲女士；及本公司獨立非執行董事為張影博士、賈慶豐先生及謝丹博士。 * 僅供識別 美因基因有限公司 執行董事兼主席 林琳 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 內部監控審查的範圍包括審查本集團的財務流程、系統和內部控制要素（合稱「內部控 制」），涵蓋期間為2025年7月8日至2025年7月23日。後續審查涵蓋期間為2025年7月25日 至2025年12月1日。 內部監控審查之主要發現及結果 於內部監控審查期間，外部獨立顧問已列出本集團內部監控系統及程序的發現，包括獨 立調查公司於獨立法證調查中發現之缺陷，並向本集團管理層提出補救該等發現之建 議。本集團管理層已根據外部獨立顧問的推薦建議作出回應及採取適當措施。根據後續 審查，外部獨立顧問提出的所有建議整改已獲採納及實施。 –2– Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 內幕消息 內部監控審查主要發現 及 繼續暫停交易 本公告乃由美因基因有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證 ...